Optimizing NF1 Tumor Management Across the Lifespan Integrating Pain and Quality-of-Life Assessment into MEK Inhibitor and Surgical Decision-Making

Neurofibromatosis type 1 (NF1) is a rare, lifelong genetic condition that can predispose individuals to tumor development. Among these are NF1-associated plexiform neurofibromas (PNs), infiltrative tumors that can be difficult to treat surgically, cause significant pain, and profoundly impact quality of life. The emergence of MAPK/ERK kinase (MEK) inhibitors has reshaped the treatment landscape, creating new opportunities for proactive, systemic management of NF1-PN. Because NF1 is rare, however, many clinicians have limited familiarity with evolving diagnostic frameworks, treatment selection, and strategies for managing long-term treatment-related toxicities. At the same time, fragmented communication across multidisciplinary teams can make it difficult to address the complex, cross-specialty needs of patients. Targeted education can empower clinicians and care teams to strengthen interprofessional decision-making, enhance diagnostic precision, apply evidence-based therapies, and mitigate toxicity across both pediatric and adult populations living with NF1-PNs. In this CE Concepts livestream symposium, expert faculty will incorporate patient-reported pain and quality-of-life data into treatment decision-making for patients with NF1-associated plexiform neurofibromas. Learners will be shown how to assess evidence based strategies for integrating MEK inhibitor therapy with surgery in the multidisciplinary management of patients with NF1 PNs. Faculty will discuss structured, evidence-based strategies to anticipate, monitor, and manage MEK inhibitor-related toxicities in patients with NF1-PNs while maintaining dose intensity and minimizing treatment discontinuation across pediatric and adult care settings.